Kuijpers Chantal C H J, Sluijter Caro E, von der Thüsen Jan H, Grünberg Katrien, van Oijen Martijn G H, van Diest Paul J, Jiwa Mehdi, Nagtegaal Iris D, Overbeek Lucy I H, Willems Stefan M
Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Foundation PALGA (the Nationwide Network and Registry of Histo- and Cytopathology in The Netherlands), Houten, The Netherlands.
Histopathology. 2016 Aug;69(2):187-97. doi: 10.1111/his.12923. Epub 2016 Feb 14.
Although high-grade dysplasia (HGD) is a risk factor for malignant transformation and the future development of adenomas/carcinomas, grade is not incorporated in the Dutch guidelines for colonoscopy surveillance, partly because of presumed interobserver variability. The aim of this study was to analyse, in a nationwide cohort of colorectal adenomas, the interlaboratory variability in the grading of dysplasia in daily practice.
From the Dutch Pathology Registry, all synoptically reported classic adenomas in The Netherlands in 2013 were identified. The proportion of adenomas with HGD was determined for biopsies and polypectomies, and compared between 37 laboratories by the use of multivariable logistic regression analyses. In total, 21 030 colonoscopies of 20 270 patients were included. HGD was reported in 530 (3.6%) of 14 866 adenomas diagnosed on biopsies (range between laboratories: 0-13.6%) and in 983 (11.8%) of 8346 adenomas diagnosed on polypectomies (range: 3.1-42.9%). After adjustment for case mix, 13 (35%) laboratories reported a significantly lower or higher frequency of HGD than average.
We observed considerable interlaboratory variation in the grading of dysplasia in colorectal adenomas, which could be only partly explained by differences in case mix. Therefore, better standardization of grading criteria is needed before grade of dysplasia can usefully be incorporated in colonoscopy surveillance guidelines.
尽管高级别异型增生(HGD)是恶性转化以及腺瘤/癌未来发展的一个风险因素,但荷兰结肠镜监测指南并未纳入分级,部分原因是假定存在观察者间差异。本研究的目的是在一个全国性的大肠腺瘤队列中分析日常实践中实验室间异型增生分级的差异。
从荷兰病理登记处识别出2013年荷兰所有按摘要报告的经典腺瘤。确定活检和息肉切除术中伴有HGD的腺瘤比例,并通过多变量逻辑回归分析在37个实验室之间进行比较。总共纳入了20270例患者的21030次结肠镜检查。在活检诊断的14866例腺瘤中,530例(3.6%)报告有HGD(各实验室范围:0 - 13.6%);在息肉切除术中诊断的8346例腺瘤中,983例(11.8%)报告有HGD(范围:3.1 - 42.9%)。在对病例组合进行调整后,13个(35%)实验室报告的HGD频率显著低于或高于平均水平。
我们观察到大肠腺瘤异型增生分级在实验室间存在相当大的差异,这只能部分地由病例组合差异来解释。因此,在异型增生分级能够有效纳入结肠镜监测指南之前,需要更好地规范分级标准。